Reuters logo
BRIEF-Argenx publishes preclinical data on ARGX-116
August 23, 2017 / 5:07 AM / 4 months ago

BRIEF-Argenx publishes preclinical data on ARGX-116

Aug 23 (Reuters) - ARGENX NV:

* PUBLICATION OF PRECLINICAL DATA ON ARGX-116 INHIBITING APOC3 PROVIDING FURTHER RATIONALE FOR THERAPEUTIC POTENTIAL OF ANTI-APOC3 SIMPLE ANTIBODY(TM) ARGX-116

* DATA PUBLISHED DEMONSTRATE THAT ARGX-116 ACCELERATES APOC3 CLEARANCE AND LOWERS TRIGLYCERIDE-RICH LIPOPROTEINS (TRL) IN MOUSE MODELS

* THESE DATA COULD TRANSLATE TO A POSSIBLE APPROACH TO REDUCE APOC3 LEVELS AND CIRCULATING TRL BURDEN IN VIVO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below